Role of aggressive surgical cytoreduction in advanced ovarian cancer / 부인종양
Journal of Gynecologic Oncology
;
: 336-342, 2015.
Article
Dans Anglais
| WPRIM
| ID: wpr-123432
ABSTRACT
Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de l'ovaire
/
Types de pratiques des médecins
/
Biais de l'observateur
/
Essais contrôlés randomisés comme sujet
/
Études rétrospectives
/
Maladie résiduelle
/
Médecine factuelle
/
Interventions chirurgicales de cytoréduction
Type d'étude:
Étude observationnelle
Limites du sujet:
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Journal of Gynecologic Oncology
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS